Takeda Acquires GammaDelta Therapeutics

Takeda Acquires Adaptate Biotherapeutics

January 10, 2022

Biotechnology

Takeda Pharmaceutical Company Limited has exercised its option to acquire Adaptate Biotherapeutics, a UK biotechnology spin-out focused on antibody-based γδ T cell engager therapies for solid tumors. The acquisition gives Takeda Adaptate’s antibody-based γδ T cell engager platform and preclinical pipeline to strengthen Takeda’s immuno-oncology capabilities and accelerate development of Vδ1‑targeting therapies.

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Takeda Pharmaceutical Company Limited Acquires Maverick Therapeutics, Inc.

March 9, 2021

Biotechnology

Takeda exercised its option to acquire Maverick Therapeutics, obtaining Maverick's COBRA conditionally active bispecific T‑cell engager platform and lead development candidates (TAK‑186 and TAK‑280). The deal, based on a prior collaboration and equity stake, is structured for up to $525 million in upfront and potential milestone payments and will fold Maverick's R&D team into Takeda's organization.

Talend Acquires Gamma Soft

April 7, 2022

Software

Talend has acquired Gamma Soft, a Paris-based provider of change data capture (CDC) technology, to deepen Talend's real-time data replication and CDC capabilities. The acquisition is intended to accelerate customers' cloud migrations and real-time analytics use cases by embedding Gamma Soft's CDC functionality into Talend's data integration and management platform.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Biotechnology

Gilead Sciences has completed the acquisition of CymaBay Therapeutics for approximately $4.3 billion, paying $32.50 per share in cash. The deal adds CymaBay's investigational PPARδ agonist seladelpar for primary biliary cholangitis (PBC) to Gilead's liver-disease portfolio and is expected to accelerate development and potential commercialization of the therapy.